Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients

Research output: Contribution to journalArticle

Abstract

All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia (APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted in complete remission rates >90 % and long-term remission rates above 80 %. Furthermore, the combination of ATRA and arsenic trioxide (ATO) was shown to be safe and effective in frontline treatment and, for patients with low and intermediate risk disease, possibly superior to the standard ATRA and anthracycline-based regimen. However, in spite of this tremendous progress, APL still remains associated with a high incidence of early death due to the frequent occurrence of an abrupt bleeding diathesis. This hemorrhagic syndrome more frequently develops in high-risk APL patients, currently defined as those exhibiting >10 × 109/L WBC at presentation. In addition to high WBC count, other molecular and immunophenotypic features have been associated with high-risk APL. Among them, the expression in APL blasts of the stem/progenitor cell antigen CD34, the neural adhesion molecule (CD56), and the T cell antigen CD2 help to identify a subset of patients at higher risk of relapse and often the expression of these markers is associated with high WBC count. At the molecular level, the short PML/RARA isoform and FLT3-internal tandem duplication (ITD) mutations have been associated with increased relapse risk. These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease.

Original languageEnglish
Pages (from-to)673-680
Number of pages8
JournalAnnals of Hematology
Volume95
Issue number5
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
CD34 Antigens
CD56 Antigens
CD2 Antigens
Stem Cells
Recurrence
Mutation
Anthracyclines
Viral Tumor Antigens
Disease Susceptibility
Therapeutics
Combination Drug Therapy
Protein Isoforms
Leukemia
Hemorrhage
T-Lymphocytes
Incidence

Keywords

  • Acute myeloid leukemia
  • Acute promyelocytic leukemia
  • Membrane markers
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Prognostic factors in acute promyelocytic leukemia : strategies to define high-risk patients. / Testa, Ugo; Lo-Coco, Francesco.

In: Annals of Hematology, Vol. 95, No. 5, 01.04.2016, p. 673-680.

Research output: Contribution to journalArticle

@article{fad0334ba687401aa0a8fb3c5af6c2bc,
title = "Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients",
abstract = "All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia (APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted in complete remission rates >90 {\%} and long-term remission rates above 80 {\%}. Furthermore, the combination of ATRA and arsenic trioxide (ATO) was shown to be safe and effective in frontline treatment and, for patients with low and intermediate risk disease, possibly superior to the standard ATRA and anthracycline-based regimen. However, in spite of this tremendous progress, APL still remains associated with a high incidence of early death due to the frequent occurrence of an abrupt bleeding diathesis. This hemorrhagic syndrome more frequently develops in high-risk APL patients, currently defined as those exhibiting >10 × 109/L WBC at presentation. In addition to high WBC count, other molecular and immunophenotypic features have been associated with high-risk APL. Among them, the expression in APL blasts of the stem/progenitor cell antigen CD34, the neural adhesion molecule (CD56), and the T cell antigen CD2 help to identify a subset of patients at higher risk of relapse and often the expression of these markers is associated with high WBC count. At the molecular level, the short PML/RARA isoform and FLT3-internal tandem duplication (ITD) mutations have been associated with increased relapse risk. These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease.",
keywords = "Acute myeloid leukemia, Acute promyelocytic leukemia, Membrane markers, Prognosis",
author = "Ugo Testa and Francesco Lo-Coco",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s00277-016-2622-1",
language = "English",
volume = "95",
pages = "673--680",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Prognostic factors in acute promyelocytic leukemia

T2 - strategies to define high-risk patients

AU - Testa, Ugo

AU - Lo-Coco, Francesco

PY - 2016/4/1

Y1 - 2016/4/1

N2 - All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia (APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted in complete remission rates >90 % and long-term remission rates above 80 %. Furthermore, the combination of ATRA and arsenic trioxide (ATO) was shown to be safe and effective in frontline treatment and, for patients with low and intermediate risk disease, possibly superior to the standard ATRA and anthracycline-based regimen. However, in spite of this tremendous progress, APL still remains associated with a high incidence of early death due to the frequent occurrence of an abrupt bleeding diathesis. This hemorrhagic syndrome more frequently develops in high-risk APL patients, currently defined as those exhibiting >10 × 109/L WBC at presentation. In addition to high WBC count, other molecular and immunophenotypic features have been associated with high-risk APL. Among them, the expression in APL blasts of the stem/progenitor cell antigen CD34, the neural adhesion molecule (CD56), and the T cell antigen CD2 help to identify a subset of patients at higher risk of relapse and often the expression of these markers is associated with high WBC count. At the molecular level, the short PML/RARA isoform and FLT3-internal tandem duplication (ITD) mutations have been associated with increased relapse risk. These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease.

AB - All trans retinoic acid (ATRA) has revolutionized the therapy of acute promyelocytic leukemia (APL). Treatment of this leukemia with ATRA in combination with chemotherapy has resulted in complete remission rates >90 % and long-term remission rates above 80 %. Furthermore, the combination of ATRA and arsenic trioxide (ATO) was shown to be safe and effective in frontline treatment and, for patients with low and intermediate risk disease, possibly superior to the standard ATRA and anthracycline-based regimen. However, in spite of this tremendous progress, APL still remains associated with a high incidence of early death due to the frequent occurrence of an abrupt bleeding diathesis. This hemorrhagic syndrome more frequently develops in high-risk APL patients, currently defined as those exhibiting >10 × 109/L WBC at presentation. In addition to high WBC count, other molecular and immunophenotypic features have been associated with high-risk APL. Among them, the expression in APL blasts of the stem/progenitor cell antigen CD34, the neural adhesion molecule (CD56), and the T cell antigen CD2 help to identify a subset of patients at higher risk of relapse and often the expression of these markers is associated with high WBC count. At the molecular level, the short PML/RARA isoform and FLT3-internal tandem duplication (ITD) mutations have been associated with increased relapse risk. These observations indicate that extended immunophenotypic and molecular characterization of APL at diagnosis including evaluation of CD2, CD56, and CD34 antigens and of FLT3 mutations may help to better design risk-adapted treatment in this disease.

KW - Acute myeloid leukemia

KW - Acute promyelocytic leukemia

KW - Membrane markers

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84962097056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962097056&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2622-1

DO - 10.1007/s00277-016-2622-1

M3 - Article

C2 - 26920716

AN - SCOPUS:84962097056

VL - 95

SP - 673

EP - 680

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -